Ryan P. McMurray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan P. McMurray has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Asad Umar
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
104 shared publications - Carrie Strand
Mayo Clinic 4 , Rochester, Minnesota
104 shared publications - Ellen Richmond
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
104 shared publications - Luz Maria Rodriguez
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
104 shared publications - Marcia Cruz-Correa
University of Puerto Rico, San Juan, Puerto Rico
104 shared publications - Nathan R. Foster
Mayo Clinic 4 , Rochester, Minnesota
104 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S4. Representativeness of Study Participants.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S4. Representativeness of Study Participants.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S1 shows boxplots of gastric mucosal IL-1β concentrations at baseline, 6 months, and the change from baseline to 6 months, stratified by treatment arm (placebo vs. curcumin), including both gastric antrum and corpus samples.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S1 shows boxplots of gastric mucosal IL-1β concentrations at baseline, 6 months, and the change from baseline to 6 months, stratified by treatment arm (placebo vs. curcumin), including both gastric antrum and corpus samples.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori.Prevention Relevance:Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction.See related Spotlight, p. 387See related article by Morgan et al., p. 391
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori.Prevention Relevance:Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction.See related Spotlight, p. 387See related article by Morgan et al., p. 391
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S2 shows boxplots of gastric mucosal cytokine and chemokine concentrations (IL-8, TNFα, and IP-10) at baseline, 6 months stratified by treatment arm and presented separately for antrum and corpus specimens.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S2 shows boxplots of gastric mucosal cytokine and chemokine concentrations (IL-8, TNFα, and IP-10) at baseline, 6 months stratified by treatment arm and presented separately for antrum and corpus specimens.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S1 provides the completed CONSORT 2010 checklist summarizing trial design, methodology, reporting elements, and corresponding manuscript page numbers.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S1 provides the completed CONSORT 2010 checklist summarizing trial design, methodology, reporting elements, and corresponding manuscript page numbers.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S3 presents summary statistics for gastric mucosal cytokine and chemokine concentrations (IL-1β, IL-8, TNFα, IP-10) at baseline and 6 months by treatment arm, including measures of central tendency, dispersion, and nonparametric between-group comparisons.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S3 presents summary statistics for gastric mucosal cytokine and chemokine concentrations (IL-1β, IL-8, TNFα, IP-10) at baseline and 6 months by treatment arm, including measures of central tendency, dispersion, and nonparametric between-group comparisons.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S3 shows boxplots of gastric mucosal cytokine and chemokine concentrations (IL-8, TNFα, and IP-10) changes between baseline and 6 months stratified by treatment arm and presented separately for antrum and corpus specimens.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S3 shows boxplots of gastric mucosal cytokine and chemokine concentrations (IL-8, TNFα, and IP-10) changes between baseline and 6 months stratified by treatment arm and presented separately for antrum and corpus specimens.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S4 shows the distribution of Correa cascade histopathology scores at baseline and 6 months, comparing treatment arms and illustrating changes in premalignant gastric lesions over time.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Figure S4 shows the distribution of Correa cascade histopathology scores at baseline and 6 months, comparing treatment arms and illustrating changes in premalignant gastric lesions over time.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S2 summarizes all reported adverse events by treatment arm, categorized by organ system, event type, severity grade, and frequency, regardless of attribution.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Supplementary Table S2 summarizes all reported adverse events by treatment arm, categorized by organ system, event type, severity grade, and frequency, regardless of attribution.
- Open Access
- 29 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (7) , OF1-OF11
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori. Prevention Relevance: Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction. See related article by Morgan et al., p. XX . See related article by Park and Moy, p. XX .
- 29 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (7) , OF1-OF11
Open AccessRandomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Globally, gastric adenocarcinoma is the fourth leading cause of cancer mortality and a major cancer disparity in the United States. Chemoprevention strategies are lacking for high-risk individuals with gastric premalignant conditions (GPMC). Curcumin, the principal curcuminoid in turmeric, exerts immunomodulatory effects in the epithelium and against Helicobacter pylori, and studies suggest chemoprevention potential. We conducted a double-blind, phase IIa randomized controlled trial in high-risk populations in Puerto Rico and Honduras. We investigated the utility of a bioavailable formulation of curcumin (Meriva) among individuals with H. pylori–negative GPMC, specifically, multifocal atrophic gastritis (MAG) or gastric intestinal metaplasia (GIM). Patients were 1:1 randomized to 1,000 mg Meriva daily or placebo for a 6-month intervention with endoscopy at baseline and 6 months. Outcomes included assessment of epithelial cytokine and chemokine levels, histology, and DNA damage as assessed by γ-H2AX phosphorylation IHC. Of the 110 subjects screened, 50 participants were randomized, and 48 completed the trial. A significant reduction in gastric mucosal IL1β levels from baseline in the gastric body, the primary endpoint, was observed in the Meriva group (P = 0.032). Changes in epithelial IL8, TNFα, and inducible protein 10 levels and gastric mucosal histology and DNA damage (secondary endpoints) were similar between arms. Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori–negative patients with GPMC. A potential reduction in gastric inflammation as measured by gastric mucosal IL1β levels was observed. Further studies are warranted, including studies in H. pylori–positive individuals, based upon the curcuminoid direct effects on H. pylori. Prevention Relevance: Gastric adenocarcinoma is a leading cause of cancer mortality worldwide. Chemoprevention candidates for GPMCs are limited. This randomized phase IIa trial evaluated a bioavailable curcumin formulation in high-risk individuals with MAG and GIM. The results support further study of curcuminoids for gastric cancer risk reduction. See related article by Morgan et al., p. XX . See related article by Park and Moy, p. XX .